Effect of 3-month Treatment With F2695 (75mg OD) on Improving Functional Recovery of Patients With Ischemic Stroke. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study

Trial Profile

Effect of 3-month Treatment With F2695 (75mg OD) on Improving Functional Recovery of Patients With Ischemic Stroke. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Levomilnacipran (Primary)
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms LIFE
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 31 Mar 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 18 Nov 2014 Planned End Date changed from 1 Jan 2015 to 1 Feb 2015, according to ClinicalTrials.gov record.
    • 18 Nov 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Feb 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top